1. Introduction
===============

Nonalcoholic fatty liver disease (NAFLD) is a common and complex liver disease, with the risk factors including central obesity, dyslipidemia, hypertension, insulin resistance (IR), and type 2 diabetes mellitus (T2DM) \[[@B1-ijms-16-05161],[@B2-ijms-16-05161]\]. Patients with NAFLD may develop non-alcoholic steatohepatitis (NASH), which is defined as hepatic steatosis and inflammation or liver cell injury, with or without fibrosis \[[@B3-ijms-16-05161],[@B4-ijms-16-05161]\]. NASH may progresss to fibrosis or cirrhosis \[[@B5-ijms-16-05161]\], leading to hepatocellular carcinoma (HCC) \[[@B6-ijms-16-05161]\] and even liver-related mortality \[[@B7-ijms-16-05161]\]. Due to unhealthy lifestyles and dietary patterns, the population of obese individuals has increased globally over the past few decades. NAFLD has become the most common cause of liver disorders worldwide \[[@B8-ijms-16-05161]\]. In China, the reported prevalence of NAFLD is about 15% among the adults in the mainland and 27.3% in Hong Kong adults \[[@B8-ijms-16-05161],[@B9-ijms-16-05161],[@B10-ijms-16-05161]\], but the proportion of NAFLD patients with liver fibrosis is low (3.7%) \[[@B11-ijms-16-05161]\]. Several studies have shown that 26%--37% of patients with NASH will progress to hepatic fibrosis and 9% to cirrhosis over the next six years \[[@B12-ijms-16-05161],[@B13-ijms-16-05161],[@B14-ijms-16-05161]\]. Based on long term follow-up studies, the prevalence of HCC is 0%--0.5% in NAFLD patients and 0%--2.8% in NASH patients \[[@B15-ijms-16-05161],[@B16-ijms-16-05161]\].

The pathogenesis of NAFLD is multi-faceted and complicated. The liver plays a major role in lipid and glucose metabolism and NAFLD represents impaired homeostasis of the metabolism \[[@B17-ijms-16-05161]\]. In the well-recognized double-hit theory of the pathogenesis of NAFLD, the first hit is the accumulation of triglycerides (TG) in hepatocytes, followed by a second hit in which inflammatory mediators cause hepatocellular injury, inflammation, and fibrosis \[[@B18-ijms-16-05161],[@B19-ijms-16-05161],[@B20-ijms-16-05161]\]. Studies performed over the past few years have described a new model in which multiple parallel hits might be responsible for the development of NAFLD. Fatty acids and the metabolites facilitate the development of simple steatosis (SS) to NASH. IR enhances the recruitment of free fatty acids from the circulation and hepatic deposition of free acids, which activates endoplasmic reticulum (ER) and oxidative stress and ultimately apoptosis of hepatocytes. Fatty acids also enhance hepatic IR, which induces a vicious cycle of lipid storage \[[@B21-ijms-16-05161],[@B22-ijms-16-05161]\].

Generally, NAFLD is caused by interactions between many environmental and genetic factors. However, the precise pathogenesis of NAFLD is not well understood. NAFLD is associated with changes at the transcriptional level that influences gene expression and phenotype \[[@B23-ijms-16-05161]\]. Although most epigenetic aberrations are transient and non-heritable, some are transgenerational \[[@B24-ijms-16-05161],[@B25-ijms-16-05161],[@B26-ijms-16-05161]\]. The most thoroughly studied markers for epigenetic alterations are DNA methylation, histone modifications, and the actions of microRNAs (miRs) \[[@B23-ijms-16-05161]\]. These processes are regulated by the environmental factors such as nutrition and diet \[[@B27-ijms-16-05161]\], drugs \[[@B28-ijms-16-05161]\], and stress \[[@B29-ijms-16-05161]\]. Epigenetic modifiers are involved in lipid metabolism, IR and ER stress, mitochondrial damage, oxidative stress, and inflammation. This can induce hepatic lipid accumulation and eventually NAFLD \[[@B30-ijms-16-05161],[@B31-ijms-16-05161],[@B32-ijms-16-05161],[@B33-ijms-16-05161]\]. Epigenetic dysregulation has been found to trigger carcinogenesis of hepatocytes and facilitate the progression of HCC \[[@B34-ijms-16-05161],[@B35-ijms-16-05161]\]. Evaluating epigenetic changes and their roles in the pathnogenesis of NAFLD would guide us to develop novel approaches for the prevention or therapy for the metabolic liver diseases.

2. DNA Methylation
==================

Aberrant DNA methylation represents one of the major epigenetic changes that contribute to abnormal gene expression in the pathogenesis of NAFLD \[[@B36-ijms-16-05161]\]. DNA methylation is catalyzed by DNA methyltransferases (DNMTs), which convert cytosine to 5-methylcytosine binding with guanine in DNA \[[@B37-ijms-16-05161]\]. DNA methylation is regarded as a key process involved in changing the liver phenotype from normal liver through SS to NASH \[[@B38-ijms-16-05161]\]. Usually, hypermethylation of CpG islands in gene promoters induces gene silencing and inhibits gene expression, and hypermethylation of the global DNA influences genomic stability \[[@B39-ijms-16-05161]\]. It is essential to understand the role of DNA methylation in nutrition and genetics.

Diet is one of the main elements that influence DNA methylation. DNA methylation relies on the availability of *S*-adenosylmethionine (SAM), and the methyl donors from foods (including folate, betaine, and choline) are associated with SAM synthesis \[[@B40-ijms-16-05161],[@B41-ijms-16-05161]\]. Folate is a catalytic substrate for transfering one-carbon units. Dysregulation of single-carbon metabolism may contribute to the hepatic steatosis by DNA methylation reaction. Folate deficiency has been proved to induce TG accumulation in the liver \[[@B42-ijms-16-05161]\]. It has been reported that folate affects the expression of genes involved in fatty acid synthesis \[[@B43-ijms-16-05161]\]. Another important methyl donor is betaine, which has been found to alleviate high-fat-diet-induced (HFD-induced) fatty livers \[[@B44-ijms-16-05161]\]. Betaine supplementation has been showed to be associated with significantly less methylation of the microsomal triglyceride transfer protein (*MTTP*) promoter and more methylation of the genome. This promotes hepatic TG export and attenuates liver steatosis in NAFLD \[[@B38-ijms-16-05161]\]. High-fat-sucrose-induced (HFS-induced) liver fat accumulation was reverted by the supplementation with methyl donors containing folic acid, choline, betaine, and Vitamin B12, which decreased the liver global DNA methylation and changed the methylation levels of CpG sites in the sterol regulatory element binding transcription factor 2 (*Srebf2*), 1-acylglycerol-3-phosphate Oacyltransferase 3 (*Agpat3*), and estrogen receptor 1 (*Esr1*) promoter regions \[[@B45-ijms-16-05161]\]. Similarly, the methyl donor supplementation mediated fatty acid synthase (*FASN*) DNA hypermethylation, which may be involved in the improvement of HFS-induced NAFLD \[[@B46-ijms-16-05161]\]. Methyl-deficient diets were found to reduce the concentration of hepatic SAM and resulted in CpG island methylation of 164 genes in mouse livers. These genes were found to be involved in DNA damage and repair, lipid and glucose metabolism, and the progression of fibrosis \[[@B47-ijms-16-05161]\].

DNA methylation can be inherited from parents and passed to the next generation through markings on the chromosome \[[@B48-ijms-16-05161]\]. It has been reported that maternal HFD can result in hepatic dysfunction in offspring during early postnatal life \[[@B49-ijms-16-05161]\]. Cyclin-dependent kinase inhibitor 1A (*CDKN1a*), an inhibitor of the hepatic cell cycle, was hypomethylated at first exon and CpG dinucleotides in maternal HFD offspring, and the upregulated expression of *CDKN1a* was found to be correlated with hepatocyte growth in pathological states \[[@B49-ijms-16-05161]\]. A similar study showed maternal Western diet during prenatal and post-weaning periods to increase the susceptibility of male offspring to NAFLD \[[@B50-ijms-16-05161]\]. It has recently been shown that melatonin can reverse the methylation of leptin and ameliorate glucocorticoid-induced hepatic steatosis \[[@B51-ijms-16-05161]\].

Peroxisome proliferator-activated receptors (*PPARs*) play a key role in adipogenesis and contribute to liver steatosis \[[@B52-ijms-16-05161]\]. The balance of *PPARα* and *PPARγ* activity is associated with the synthesis of fatty acids and oxidation. *PPARα* modulates the activity of the proteins involved in protein transport and liver cytosolic fatty acid-binding activity (e.g., fatty acid translocase). Results have shown that the expression of *PPARα* is downregulated in liver steatosis \[[@B53-ijms-16-05161]\], thereby favoring lipogenesis during oxidation. However, *PPARγ* regulates differentiation and cytokine production and has been found to reduce the expression of pro-inflammatory cytokines. One study reported that folic acid supplements could downregulate the methylation of *PPARγ* promoter and therefore upregulate the expression of *PPARγ* \[[@B54-ijms-16-05161]\]. In addition, epigenetic modifications of *PPARγ* in the liver of NAFLD patients contribute to IR. Methylation levels of liver *PPARγ* coactivator 1α (*PGC1α*) and mitochondrial transcription factor A (*TFAM*) were relevant to fasting insulin and homeostasis model assessment of IR (HOMA-IR). Also, the hepatic level of mitochondrial DNA (mtDNA) is much higher in normal livers than in the NAFLD livers and was found to be inversely associated with PGC1α methylation, fasting insulin, and HOMA-IR \[[@B55-ijms-16-05161]\].

Accumulating amounts of evidence have suggested that epigenetic variations of mtDNA methylation may occur during the development of NAFLD \[[@B56-ijms-16-05161],[@B57-ijms-16-05161]\]. Mitochondria are the major sources and targets of reactive oxygen species (ROS). Oxidative stress can result in apoptosis due to impaired proton translocation, electron transport, and ATP synthesis \[[@B58-ijms-16-05161]\]. The mitochondrially encoded NADH dehydrogenase 6 (*MT-ND6*) gene is a target of mitochondria methylation in NAFLD \[[@B32-ijms-16-05161]\]. It has been reported that *MT-ND6* is highly methylated and that there is considerably less expression of *MT-ND6* mRNA in NASH patients than in SS patients. In addition, liver methylation of *MT-ND6* was found to be related to the severity of NAFLD indicating that the epigenetic modification of mitochondrial gene plays a critical role in the development and pathogenesis of NAFLD \[[@B32-ijms-16-05161]\].

These data, which were collected in animal models of NAFLD, have also been demonstrated in human NAFLD patients. Murphy and colleagues have found 69,247 methylated CpG sites in NAFLD patients \[[@B59-ijms-16-05161]\]. Methylation of these genes is involved in tissue repair and metabolic regulation \[[@B59-ijms-16-05161]\]. Another study reported changes in the methylation of nine NAFLD-related genes coding for critical enzymes in intermediate metabolism and insulin-like signaling \[[@B60-ijms-16-05161]\]. These methylations can be partially reversed after bariatric surgery \[[@B60-ijms-16-05161]\]. Collectively, methylation modification with gene expression profiles is a powerful approach to identifying the pathophysiological pathways related to the development of NAFLD ([Table 1](#ijms-16-05161-t001){ref-type="table"}).
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###### 

Target genes related to DNA methylations and histone modifications in NAFLD.

  Mechanism                Study Subject                                                                   Target Gene(s)                                                                                                                  References
  ------------------------ ------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------
  DNA methylation          Mouse                                                                           *MTTP*                                                                                                                          Wang *et al.* \[[@B38-ijms-16-05161]\]
  Rat                      *Srebf2*, *Agpat3*, *Esr1*                                                      Cordero *et al.* \[[@B45-ijms-16-05161]\]                                                                                       
  Rat                      *FASN*                                                                          Cordero *et al.* \[[@B46-ijms-16-05161]\]                                                                                       
  Rat                      *CDKN1a*                                                                        Dudley *et al.* \[[@B49-ijms-16-05161]\]                                                                                        
  Mouse                    *PPARα*, *INSIG*, and *FASN*                                                    Pruis *et al.* \[[@B50-ijms-16-05161]\]                                                                                         
  Rat                      *Leptin*                                                                        Tiao *et al.* \[[@B51-ijms-16-05161]\]                                                                                          
  Rat                      *PPARγ*                                                                         Sie *et al.* \[[@B54-ijms-16-05161]\]                                                                                           
  Human                    *PGC1α*, *TFAM*                                                                 Sookoian *et al.* \[[@B55-ijms-16-05161]\]                                                                                      
  Human                    *MT-ND6*                                                                        Pirola *et al.* \[[@B32-ijms-16-05161]\]                                                                                        
  Human                    *PC*, *ACLY*, *PLCG1*, *IGF1*, *IGFBP2*, *PRKCE*, *GALNTL4*, *GRID1*, *IP6K3*   Ahrens *et al.* \[[@B60-ijms-16-05161]\]                                                                                        
  Histone modificaitions   Macaques                                                                        *GPT2*, *DNAJA2*, *Rdh12*, *Npas2*                                                                                              Aagaard-Tillery *et al.* \[[@B61-ijms-16-05161]\]
  Mouse                    *ChREBP*                                                                        Bricambert *et al.* \[[@B62-ijms-16-05161]\]                                                                                    
  Mouse                    *CYP8B1*                                                                        Pathak *et al.* \[[@B63-ijms-16-05161]\]                                                                                        
  Mouse                    *TNFα*, *CCL2*                                                                  Mikula *et al.* \[[@B64-ijms-16-05161]\]                                                                                        
  Mouse                    *PPARα* and related network genes                                               Jun *et al.* \[[@B65-ijms-16-05161]\]                                                                                           
  Mouse                    *ERO1α*, *LXRα*                                                                 Li *et al.* \[[@B33-ijms-16-05161]\]                                                                                            
  Mouse                    *SIRT1/macroH2A1.1*, *SIRT3*                                                    Cao *et al.* \[[@B66-ijms-16-05161]\]; Hirschey *et al.* \[[@B67-ijms-16-05161]\]; Pazienza *et al.* \[[@B68-ijms-16-05161]\]   
  Human                    NER                                                                             Schults *et al.* \[[@B69-ijms-16-05161]\]                                                                                       

*MTTP* (microsomal triglyceride transfer protein), *Srebf2* (sterol regulatory element binding transcription factor 2), *Agpat3* (1-acylglycerol-3-phosphate oacyltransferase 3), *Esr1* (estrogen receptor 1), FASN (fatty acid synthase), *CDKN1a* (cyclin-dependent kinase inhibitor 1a), *PPARα* (peroxisome proliferator-activated receptors α), *INSIG* (insulin-induced gene), *PGC1α* (PPARγ coactivator 1α), *TFAM* (mitochondrial transcription factor A), *MT-ND6* (mitochondrially encoded NADH dehydrogenase 6), *PC* (pyruvate carboxylase), *ACLY* (ATP citrate lyase), *PLCG1* (phospholipase C-gamma-1), *IGF1* (insulin-like growth factor 1), *IGFBP2* (insulin-like growth factor binding protein 2), *PRKCE* (protein kinase C, epsilon), *GALNTL4* (putative polypeptide *N*-acetylgalactosaminyltransferase-like protein 4), *GRID1* (glutamate receptor δ-1 IP6K3 Inositol hexaphosphate kinase 3), *GPT2* (glutamic pyruvate transaminase 2), *DNAJA2* (DnaJ (Hsp40) homolog, subfamily A, member 2), *Rdh12* (retinol dehydrogenase 12), *Npas2* (neuronal PAS domain-containing protein 2), *ChREBP* (carbohydrate-responsive element-binding protein), *CYP8B1* (sterol 12α-hydroxylase), *TNFα* (tumor necrosis factor α), *CCL2* (chemokine C--C motif ligand 2), *ERO1α* (oxireductase endoplasmic reticulum oxidoreductin1α), *LXRα* (liver X receptor α), *SIRT1* (sirtuin 1), and NER (nucleotide excision repair).

3. Histone Modifications
========================

Histone modifications mainly consist of acetylation, methylation, phosphorylation, and ubiquitylation. Among them, the histone acetylation patterns are the most heavily studied pattern. They are known to be regulated by histone acetyltransferases (HATs) and histone deacetylases (HDACs). To date, ample amounts of evidence have indicated changes in histone acetylation in NAFLD ([Table 1](#ijms-16-05161-t001){ref-type="table"}, \[[@B61-ijms-16-05161],[@B62-ijms-16-05161]\]). Studies in Japanese macaques have shown that a significant hyperacetylation of H3K14 in the fetal hepatic tissue was accompanied by upregulated acetylation at H3K9 and H3K18 \[[@B61-ijms-16-05161]\]. A high-fat maternal diet was found to induce the depletion of HDAC1 protein in the fetal liver \[[@B61-ijms-16-05161]\]. These findings indicate that HFD-induced maternal obesity can change fetal chromatin structure via histone modifications \[[@B61-ijms-16-05161]\]. Carbohydrate-responsive element-binding protein (*ChREBP*) is a fundamental regulator in the progression of NAFLD. It acts as a transcriptional activator of lipogenic and glycolytic genes. It has been reported that HAT activator p300 and serine/threonine kinase salt-inducible kinase 2 (*SIK2*) are major upstream regulators of *ChREBP* activity. Glucose-activated p300 induced *ChREBP* hyperacetylation can promote its transcriptional activity. *SIK2* reduced *p300* HAT activity by phosphorylating Ser89. This attenuated *ChREBP*-mediated hepatic lipogenesis in mice. Both knockdown of *SIK2* and overexpression of *p300* exhibited led to hepatic steatosis and IR. The findings implicate that specific *SIK2* activators and *p300* inhibitors may be useful in pharmaceutical intervention of NAFLD \[[@B62-ijms-16-05161]\]. Sterol 12α-hydroxylase (*CYP8B1*) is involved in cholic acid synthesis and cholesterol absorption. Retinoic acid-related orphan receptor α (*RORα*) recruited cAMP to induce histone acetylation of *CYP8B1* gene promoter. *RORα* is a major regulator of fasting induction and circadian rhythm of *CYP8B1*, which regulates bile acid synthesis and cholesterol levels. Antagonizing *RORα* activity might be a novel therapeutic strategy for the treatment of NAFLD and T2DM \[[@B63-ijms-16-05161]\]. Tumor necrosis factor α (*TNFα*) and chemokine C-C motif ligand 2 (*CCL2*) are the important inflammatory mediators in the development of NAFLD. Chromatin immunoprecipitation assay showed an increase in histone H3 lysine 9 and 18 acetylation at *TNFα* and *CCL2* in mice with obesity \[[@B64-ijms-16-05161]\]. These results suggest that high levels of expression of *TNFα* and *CCL2* at the chromatin level in fatty liver is associated with the alterations in histone H3 acetylation \[[@B64-ijms-16-05161]\].

Data have shown that NAFLD is correlated with changes in the transcriptome caused by histone trimethylaton. Results have shown that hepatic lipid accumulation led to the aberrant histone H3K4 and H3K9 trimethylation in *PPARα* and lipid catabolism related genes, which increased the mRNA expression of these genes in HFD-fed mice. Results suggested that histone H3K4 an H3K9 trimethylation may contribute to hepatic steatosis and disease progression \[[@B65-ijms-16-05161]\]. Lipogenesis and ER stress were promoted with the transgenerational alteration for oxireductase endoplasmic reticulum oxidoreductin1α (*ERO1α*), liver X receptor α (*LXRα*), histone methylations, and H3K9 histone methyltransferase. Low levels of accumulation of methylated histones in *ERO1-α* and *LXRα* gene promoters render the offsprings of HFD-induced mothers susceptible to hepatic steatosis and obesity \[[@B33-ijms-16-05161]\].

Sirtuins (*SIRTs*) are part of the silent information regulator-2 family. Among the seven different sirtuins, *SIRT1* has been studied the most. Studies revealed that the deacetylation of *SIRT1* is responsible for the regulation of a variety of proteins that are involved in the pathophysiology of NAFLD \[[@B70-ijms-16-05161]\]. *SIRT1* is involved in the regulation of glucose homeostasis, antihyperlipidemic activity, insulin sensitivity, oxidative stress, anti-inflammatory activity, and anti-aging activity \[[@B70-ijms-16-05161]\]. Some studies have revealed a significant reduction in the expression of *SIRT1* in NAFLD animal models, and natural *SIRT1* activator showed protective effects on metabolic diseases \[[@B71-ijms-16-05161]\]. Maternal HFD increased the fetal acetylation of histone H3K14 and decreased *SIRT1* expression in fetal livers. Maternal HFD altered the expression of downstream effector in NAFLD by regulating *SIRT1*. *SIRT1* maintains deacetylase activity on the peptide substrate of H3K14 acetylation *in vitro*. This activity may be abrogated due to the mutation of the catalytic domain of *SIRT1*. *SIRT1* modulates the fetal metabolome and epigenome as a molecular mediator under maternal HFD conditions \[[@B72-ijms-16-05161]\]. Menin deficiency enhanced liver steatosis in HFD-fed mice. The adaptor menin recruits *SIRT1* to regulate *CD36* expression and triglyceride accumulation via histone deacetylation \[[@B66-ijms-16-05161]\]. Conversely, *SIRT3* resides at the mitochondria and modulates fatty acid oxidation. HFD feeding results in hepatic mitochondrial protein hyperacetylation and decreases the *SIRT3* expression. *SIRT3* knockout mice developed hepatic steatosis and IR in the mice fed with HFD \[[@B67-ijms-16-05161]\]. In this way, *SIRT1* and *SIRT3* are involved in the balance of metabolic and hepatic steatosis regulation through the epigenetic modification.

*MacroH2A1*, a target of *SIRT1*, is a variant of histone H2A and have two isoforms *macroH2A1.1* and *macroH2A1.2*. As an important transcriptional regulator, *macroH2A1* is involved in cell senescence and tumorigenic processes. The enhanced expression of *macroH2A1.1* reduced lipid deposition in hepatocytes, whereas *macroH2A1.2* was unable to do so. *MacroH2A1.1* ameliorated glucose metabolism and downregulated the expression of lipidogenic genes. Thus, *SIRT1/macroH2A1.1*-specific epigenetic regulation of lipid metabolism is associated with NAFLD development \[[@B68-ijms-16-05161]\].

When NAFLD progressed to liver cancer, inflammation and oxidative stress played a critical role in the process. Inflammation activated neutrophil-mediated oxidative stress, which led to the reduced capacity of nucleotide excision repair (NER). Oxidative DNA damage further increased the risk of carcinogenesis in inflammatory tissues. Schults and colleagues proposed an attractive mechanism of the development of liver cancer in NAFLD patients. They observed that the neutrophilic influx with high expression of myeloperoxidase inhibited the damage recognition capacity, as indicated by staining for histone 2AX phosphorylation, which was paralleled by a reduction in NER capacity under hepatic inflammation conditions. Therefore, the reduction of NER capacity in the context of hepatic inflammation may have been caused by the reduced damage recognition \[[@B69-ijms-16-05161]\].

4. MicroRNAs
============

MiRs are small, highly conserved noncoding RNAs of approximately 18--25 nucleotides in length that modulate translation and transcription of target genes. MiRs regulate a variety of biological functions in animals and human \[[@B73-ijms-16-05161]\]. It appears that most miRs are repressed by epigenetic methylation of CpG islands \[[@B73-ijms-16-05161]\]. MiRs perform a vital role in lipid metabolism and inflammation, some of which has been reported to be epigenetically regulated in NAFLD \[[@B74-ijms-16-05161],[@B75-ijms-16-05161],[@B76-ijms-16-05161]\]. The miR alterations associated with NAFLD are summarized in [Table 2](#ijms-16-05161-t002){ref-type="table"}. The miRs analysis showed a marked decrease in miR-122, miR-451, and miR-27 and increase in miR-200a, miR-200b, and miR-429 in rats fed HFD. These miRs are involved in the regulation of carbohydrate and lipid metabolism, signal transduction and apoptosis \[[@B77-ijms-16-05161]\]. HFD-induced animal models showed considerable dysregulation of miRs and target genes. For instance, miR-467b expression was found to be markedly lower in the liver tissues of mice with hepatic steatosis than in those of otherwise normal mice. This difference was found to be inversely correlated with the expression of target gene of hepatic lipoprotein lipase (LPL). The interplay between miR-467b and LPL was associated with IR \[[@B78-ijms-16-05161]\]. Decreased expression of miR-216 and miR-302a and increased expression of miR-24 were observed in the liver tissues with NAFLD, the target genes such as ATP-binding cassette transporter A1 (*ABCA1*), long-chain fatty acid elongation 6 (*ELOVL6*) and insulin-induced gene 1 (*Insig1*) are involved in hepatic fatty acid, cholesterol, and glucose metabolism \[[@B79-ijms-16-05161],[@B80-ijms-16-05161]\]. However, some miRs levels (miR-705, miR-1224, miR-182, miR-183, miR-199a-3p, miR-200b, and miR-155) were upregulated in mice with methyl-deficient diet-induced NAFLD \[[@B81-ijms-16-05161],[@B82-ijms-16-05161]\]. The polycomb group protein enhancer of zeste homolog 2 (*EZH2*) has been reported to regulate miRs by trimethylating Lys27 on histone H3. Inhibition of *EZH2* upregulated the inflammatory genes (*TNF-α* and *TGF-β*) and specific miRs (miR-200b and miR-155) and subsequently favored hepatic steatosis in NAFLD \[[@B83-ijms-16-05161]\]. One study that focused on NASH patients showed 113 miRs expressed differentially. Among them, seven remained significant (miR-132, miR-150, miR-433, miR-28-3p, miR-511, miR-517a, and miR-671). The target genes of these miRs comprise obestatin gene, insulin receptor pathway genes, and inflammation-related genes. Additionally, miR-197 and miR-99 levels were correlated with liver fibrosis in NASH patients. MiRs from visceral adipose tissue (VAT) may be involved in the pathogenesis of NAFLD. These may serve as candidate biomarkers for NASH \[[@B84-ijms-16-05161]\].
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###### 

MiRs alterations in NAFLD.

  Study Subject   Upregulated MiRs                                                                                                               Downregulated MiRs                                                                                                   References
  --------------- ------------------------------------------------------------------------------------------------------------------------------ -------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Human           miR-10b, miR-16, miR19a/b, miR-21, miR-27b-3p, miR-34a miR-122, miR125b, miR-192-5p, miR-451, miR-1290                         miR-28-3p, miR-99a, miR-132, miR-146b, miR-150, miR-181d, miR-197, miR-296-5p, miR-433, miR-511, miR-517a, miR-671   Estep *et al.* \[[@B84-ijms-16-05161]\], Tan *et al.* \[[@B85-ijms-16-05161]\], Yamada *et al.* \[[@B86-ijms-16-05161]\], Pirola *et al.* \[[@B87-ijms-16-05161]\], Celikbilek *et al.* \[[@B88-ijms-16-05161]\], Cermelli *et al.* \[[@B89-ijms-16-05161]\], Clarke *et al.* \[[@B90-ijms-16-05161]\], Miyaaki *et al.* \[[@B91-ijms-16-05161]\], Min *et al.* \[[@B92-ijms-16-05161]\], Zheng *et al.* \[[@B93-ijms-16-05161]\], Cazanave *et al.* \[[@B94-ijms-16-05161]\]
  Mouse           miR-24, miR-33a, miR-34a, miR-122, miR-155, miR-181a, miR-182, miR-183, miR-192, miR-199a-3p/5p, miR-200b, miR-705, miR-1224   miR-92b-3p, miR-216, miR-302a, miR-328-3p, miR-467b, miR-484, miR-574-5p, miR-615-3p                                 Ahn *et al.* \[[@B78-ijms-16-05161]\], Hoekstra *et al.* \[[@B79-ijms-16-05161]\], Ng *et al.* \[[@B80-ijms-16-05161]\], Dolganiuc *et al.* \[[@B81-ijms-16-05161]\], Pogribny *et al.* \[[@B82-ijms-16-05161]\], Tryndyak *et al.* \[[@B95-ijms-16-05161]\], Derdak *et al.* \[[@B96-ijms-16-05161]\], Li *et al.* \[[@B97-ijms-16-05161]\], Li *et al.* \[[@B98-ijms-16-05161]\], Miyamoto *et al.* \[[@B99-ijms-16-05161]\]
  Rat             miR-15b, miR-155, miR-200a/b, miR-429                                                                                          miR-27, miR-122, miR-451                                                                                             Alisi *et al.* \[[@B77-ijms-16-05161]\], Vella *et al.* \[[@B83-ijms-16-05161]\], Zhang *et al.* \[[@B100-ijms-16-05161]\]

Although liver biopsy is still the gold standard of histopathological diagnosis of NAFLD, its invasive nature renders its performance difficult and unsatisfactory. A different technique, serum miR paneling, is a non-invasive diagnostic biomarker of NAFLD. The study showed the serum levels of miRs to be upregulated, including those of miR-122, miR-1290, miR-27b-3p, miR-192-5p, miR-21, miR-34a miR-15b miR-16, miR-451, miR19a/b, and miR125b \[[@B85-ijms-16-05161],[@B86-ijms-16-05161],[@B87-ijms-16-05161],[@B100-ijms-16-05161]\]. Those of other miRs were lower in NAFLD patients. These included miR-146b, miR-99a, miR-181d, and miR-197 \[[@B88-ijms-16-05161]\]. These miRs were involved in cell proliferation, glucose consumption, and TG storage. Moreover, the levels of serum miRs (miR-34a, miR-122, miR-181a, miR-192, and miR-200b) were strongly associated with inflammatory activity, fibrosis stage, and liver enzyme levels \[[@B89-ijms-16-05161],[@B95-ijms-16-05161]\]. These findings suggest that the specific serum miRs may be used as noninvasive biomarkers of diagnosis and monitors of the severity of NAFLD.

MiR-122 serves as a key regulator of the metabolism of glucose and lipids in adult livers. The serum miR-122 levels remained high across the entire inductive time of NASH in mice, which was correlated with the extent of NASH \[[@B90-ijms-16-05161]\]. Mostly, miR-122 circulates in argonaute 2-free forms and is expressed in the lipid-laden hepatocytes. MiR-122 increases alanine aminotransferase level by activating the translation at multiple sites of the coding gene \[[@B87-ijms-16-05161]\]. In NAFLD patients, the hepatic miR-122 levels were lower in patients with mild steatosis than in those with severe steatosis. Conversely, patients with mild fibrosis showed higher levels of serum and hepatic miR-122 levels than patients with severe fibrosis. Consequently, the serum miR-122 level can be used as a predictive circulating marker of hepatic fibrosis in NAFLD patients \[[@B91-ijms-16-05161]\].

MiR-34a, a transcriptional target of *p53*, is involved in the pathogenesis of NAFLD. *P53* inhibitor pifithrin-α p-nitro (*PFT*) abrogated the HFD-induced overexpressing of miR-34a and activate the *SIRT/PGC1α/PPARα* axis, which diminished hepatic TG deposition and ameliorated the liver steatosis \[[@B96-ijms-16-05161]\]. NAFLD is also associated with free cholesterol and TG accumulation. NAFLD enhanced *SREBP-2* maturation, and reduced phosphorylation of HMG CoA reductase (HMGCR). MiR-34a overexpression repressed *SIRT1* with adenosine monophosphate-activated protein kinase (AMPK) and HMGCR dephosphorylation. HMGCR expression was related to free cholesterol, the histological extent of NAFLD and LDL-cholesterol. These findings indicate that the dysregulation of cholesterol metabolism may contribute to NAFLD and cardiovascular risks \[[@B92-ijms-16-05161]\].

Based on studies, miRs participate in the regulation of some metabolism-related signal pathways. It has been proposed that cholesterol 7α-hydroxylase (*CYP7A1*)/steroid response element-binding protein 2 (*SREBP2*)/miR-33a axis performs a crucial role in the regulation of the synthesis of hepatic bile acid, cholesterol, and fatty acids. The overexpression of *CYP7A1* incerased *SREBP2*-related hepatic cholesterol synthesis and decreased hepatic fatty acid synthesis. Induction of SREBP2 subsequently activated miR-33a, which favored the lowered bile acid pool and elevated hepatic cholesterol levels in mice \[[@B97-ijms-16-05161]\]. MiR-10b was found to be correlated with the steatosis level. *PPARα*, the direct target of miR-10b, showed markedly changed protein expression. The impact of miR-10b on the regulation of hepatic steatosis may offer a novel explanation for the pathophysiology of NAFLD \[[@B93-ijms-16-05161]\]. The overexpression of miR199a-5p exacerbated fatty acid accumulation and repressed ATP levels and mtDNA content. Furthermore, miR199a-5p inhibited the expression of mitochondrial fatty acid β-oxidation-related genes via suppression of caveolin1 (CAV1) and PPARα signal pathway in obese mice and NAFLD patients. MiR199a-5p are involved in lipid metabolism and mitochondrial β-oxidation in NAFLD. MiR199a-5p overexpression may impair fatty acid β-oxidation and induce lipid deposition through the *CAV1* and *PPARα* pathway \[[@B98-ijms-16-05161]\].

Some studies have demonstrated that miRs regulate lipoapoptosis and ER stress. Lipoapoptosis is associated with the upregulation of a pro-apoptotic protein p53-upregulated mediator of apoptosis (*PUMA*). Inhibition of miR-296-5p expression was observed in the livers of NASH patients compared with healthy controls. Moreover, miR-296-5p levels were inversely correlated with *PUMA* mRNA expression in liver specimens. The data suggest that miR-296-5p regulates *PUMA* expression during hepatic lipoapoptosis and increases in miR-296-5p expression may minimize apoptotic damage in NAFLD patients \[[@B94-ijms-16-05161]\]. Palmitate is a crucial pathogenic event in NAFLD and activates the ER stress response through inducing the proapoptotic transcription factor *C/EBP* homologous protein (*CHOP*). Additionally, loss of miRs regulates lipoapoptosis under the ER stress conditions. Five miRs were downregulated under ER stress induced by palmitate in hepatocyte (miR-92b-3p, miR-328-3p, miR-484, miR-574-5p, and miR-615-3p). Enhancement of miR-615-3p levels with a precursor molecule decreased the *CHOP* expression and reduced the palmitate-induced hepatocyte apoptosis. These findings suggest elevation of miR-615-3p levels brings therapeutic benefit by suppressing palmitate-induced lipoapoptosis \[[@B99-ijms-16-05161]\].

5. Potential Epigenetic Prevention or Therapy for NAFLD
=======================================================

Currently, NAFLD therapies are limited, and some studies have focused on identification of dietary natural compounds to provide new strategies for NAFLD \[[@B101-ijms-16-05161]\]. It has been proven that dietary substances regulate fatty acid metabolism and are hypolipidemic agents \[[@B102-ijms-16-05161]\]. Folate may affect expression of miRs related to the severity of NAFLD. Folate affects miRs expression, possibly through alterations in methylation levels in the genome \[[@B103-ijms-16-05161]\]. The severity of NAFLD induced by folate-deficient diet is associated with the alteration of hepatic miRs expression, including miR-181a, miR-34a, miR-200b, and miR-221 \[[@B95-ijms-16-05161]\]. Evidence has shown that the polyphenols decrease TG synthesis and oxidative stress in the liver, increase fatty acid oxidation, and reduce the risk of metabolic diseases by regulating specific miRs such as miR-122 \[[@B104-ijms-16-05161]\]. Lycopene decreased the expression of miR-21 and its direct target fatty acid-binding protein 7 (*FABP7*) in mice fed stearic acid (SA), which blocked SA-evoked lipid accumulation. Lycopene may be used as a functional compound for NAFLD treatment \[[@B105-ijms-16-05161]\]. Especially, grape seed proanthocyanidins not only promoted liver cholesterol efflux to produce HDL particles by imhibiting miR-33, but also repressed lipogenesis by decreasing miR-122. These agents showed hepatoprotective effects through their regulation of miRs' expression associated with lipid metabolism \[[@B106-ijms-16-05161]\].

Because it has been shown the overexpression of *SIRT1* will reduce the degree of hepatic steatosis in mice NAFLD models \[[@B72-ijms-16-05161]\], activation of *SIRT1* with resveratrol, a natural *SIRT1* activator, protected against ER and IR stress and had positive effects on metabolic diseases, which is mediated by overexpression of oxygen-regulated protein 150. These findings indicated that *SIRT1* attenuated palmitate-induced ER and IR stress and the pharmacologic activation of *SIRT1* may offer a potential therapeutic strategy for NAFLD management \[[@B107-ijms-16-05161]\]. It has been demonstrated that resveratrol reduced liver lipid deposition, upregulated acyl-coenzyme A oxydase (*ACO*) and carnitine palmitoyl transferase-Ia (*CPT-Ia*), downregulated acetyl-coenzyme A carboxylase (ACC) activity, which was mediated by AMPK/SIRT1 pathway activation \[[@B102-ijms-16-05161]\]. Recently, it has been reported that hepatic steatosis could be ameliorated by drugs such as ursodeoxycholic acid (UDCA). UDCA repressed the miR-34a/SIRT1/p53 pathway in the liver of NAFLD rats. UDCA prevented miR-34a-dependent *SIRT1* suppression, *p53* acetylation, and apoptosis. Consistently, the overexpression of *p53* activated miR-34a/*SIRT1/p53*, which was in turn repressed by UDCA \[[@B108-ijms-16-05161]\]. Conclusively, these potential modulators of NAFLD pathogenesis may provide new targets for therapeutic intervention.

6. Current Problems
===================

Although the development of NAFLD is regulated by epigenetic alterations, including DNA methylation, histone modification and miRs, the investigation is just beginning and still faces many challenges. Clearly, various factors are involved in different stages of NAFLD, but the interactions among different factors and how they affect metabolistic homeostasis have not been clarified \[[@B109-ijms-16-05161]\]. In addition, so far, few effective diagnostic and therapeutic targets exist. The possible difficulty results from the complicated biomolecular interactions and overlapping pathways in the setting of NAFLD \[[@B21-ijms-16-05161]\]. It is important to exploit reliable biomolecules with high specificity and sensitivity based on the stage of NAFLD. Because epigenetic changes undergo transgenerational inheritance, animal models need to be developed to evaluate the influence of epigenetic modifications to the heritability of disease \[[@B110-ijms-16-05161]\]. Nutritional cues regulated epigenetic alterations and affect the health in the offspring. Diet could change the metabolic gene expression and increase disease susceptibility. More studies should be undertaken to identify the optimal agents from diet for the prevention and intervention of NAFLD \[[@B37-ijms-16-05161]\]. In recent years, the emergence of circulating miRs offers an option for using them as noninvasive diagnostic and therapeutic biomarkers. Nevertheless, some problems still hinder research, such as the identification of specific target miRs and the delivery mode, dosage, and period of treatment \[[@B111-ijms-16-05161]\]. In addition, with regard to the observed potential biomolecules with hepatoprotective effect, further clinical trials are needed in order to evaluate the effect and safety of the management.

7. Conclusions and Perspectives
===============================

The accumulation of epigenetic evidence related to NAFLD has offered us a novel perspective into the pathogenesis of the disease and may contribute to identifying attractive diagnostic biomarkers and therapeutic strategies for NAFLD. Further research is needed to explore the role of epigenetics in the mechanism of hepatic steatosis and steatohepatitis, the interaction of environmental factors, and epigenetic modulation, in order to promote diagnostic and therapeutic approaches as well as reduce the morbidity and mortality in NAFLD.

This work was supported by the State Key Development Program for Basic Research of China (No. 2012CB517501), the Program of the Shanghai Committee of Science and Technology (No. 10411956300), the National Natural Science Foundation of China (No. 81070322, No. 81270491, No. 81000173). Liang Qiao's work was supported by the Robert W. Storr Bequest to the Sydney Medical Foundation, University of Sydney, and a Project Grant to Liang Qiao (APP1047417), and a Cancer Council New South Wales grant to Liang Qiao (APP1070076).

Chao Sun collected the data and wrote the manuscript; Jian-Gao Fan and Liang Qiao designed this work, analyzed the data and edited the manuscript.

NAFLD

:   non-alcoholic fatty liver disease

NASH

:   non-alcoholic steatohepatitis

HCC

:   hepatocellular carcinoma

TG

:   triglycerides

SS

:   simple steatosis

IR

:   insulin resistance

ER

:   endoplasmic reticulum

miRs

:   microRNAs

DNMTs

:   DNA methyltransferases

SAM

:   S-adenosylmethionine

HFD

:   high fat diet

MTTP

:   microsomal triglyceride transfer protein

HFS

:   high-fat-sucrose

Srebf2

:   sterol regulatory element binding transcription factor 2

Agpat3

:   1-acylglycerol-3-phosphate Oacyltransferase 3

Esr1

:   estrogen receptor 1

FASN

:   fatty acid synthase

Cdkn1a

:   cyclin-dependent kinase inhibitor 1A

PPARs

:   Peroxisome proliferator-activated receptors

PGC1α

:   PPARγ coactivator 1α

TFAM

:   mitochondrial transcription factor A

HOMA-IR

:   homeostasis model assessment of IR

ROS

:   reactive oxygen species

MT-ND6

:   mitochondrially encoded NADH dehydrogenase 6

HATs

:   histone acetyltransferases

HDACs

:   histone deacetylases

ChREBP

:   carbohydrate-responsive element-binding protein

SIK2

:   serine/threonine kinase salt-inducible kinase 2

CYP8B1

:   sterol 12α-hydroxylase

RORα

:   retinoic acid-related orphan receptor α

TNFα

:   tumor necrosis factor α

CCL2

:   chemokine C-C motif ligand 2

ERO1α

:   endoplasmic reticulum oxidoreductin1α

LXRα

:   liver X receptor α

SIRTs

:   sirtuins

NER

:   nucleotide excision repair

LPL

:   lipoprotein lipase

Insig1

:   insulin-induced gene 1

ABCA1

:   ATP-binding cassette transporter A1

ELOVL6

:   long-chain fatty acid elongation 6

EZH2

:   enhancer of zeste homolog 2

VAT

:   visceral adipose tissue

PFT

:   P53 inhibitor pifithrin-α p-nitro

HMGCR

:   HMG CoA reductase

AMPK

:   adenosine monophosphate-activated protein kinase

CYP7A1

:   cholesterol 7α-hydroxylase

SREBP2

:   steroid response element-binding protein 2

CAV1

:   caveolin1

p53-upregulated mediator of apoptosis

:   PUMA

CHOP

:   C/EBP homologous protein

FABP7

:   fatty acid-binding protein 7

SA

:   stearic acid

ACO

:   acyl-coenzyme A oxydase

CPT-Ia

:   carnitine palmitoyl transferase-Ia

ACC

:   acetyl-coenzyme A carboxylase

UDCA

:   ursodeoxycholic acid

The authors declare no conflict of interest.
